- Home
- AFRI vs RCEL Comparison
AFRI vs RCEL Comparison
Compare AFRI & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFRI
- RCEL
- Stock Information
- Founded
- AFRI 1943
- RCEL N/A
- Country
- AFRI Gibraltar
- RCEL United States
- Employees
- AFRI N/A
- RCEL N/A
- Industry
- AFRI Packaged Foods
- RCEL Medical/Dental Instruments
- Sector
- AFRI Consumer Staples
- RCEL Health Care
- Exchange
- AFRI Nasdaq
- RCEL Nasdaq
- Market Cap
- AFRI 231.2M
- RCEL 240.6M
- IPO Year
- AFRI N/A
- RCEL N/A
- Fundamental
- Price
- AFRI $7.85
- RCEL $7.22
- Analyst Decision
- AFRI
- RCEL Strong Buy
- Analyst Count
- AFRI 0
- RCEL 4
- Target Price
- AFRI N/A
- RCEL $17.25
- AVG Volume (30 Days)
- AFRI 24.0K
- RCEL 150.5K
- Earning Date
- AFRI 05-13-2025
- RCEL 05-08-2025
- Dividend Yield
- AFRI N/A
- RCEL N/A
- EPS Growth
- AFRI N/A
- RCEL N/A
- EPS
- AFRI N/A
- RCEL N/A
- Revenue
- AFRI $274,223,000.00
- RCEL $64,251,000.00
- Revenue This Year
- AFRI N/A
- RCEL $62.33
- Revenue Next Year
- AFRI N/A
- RCEL $30.59
- P/E Ratio
- AFRI N/A
- RCEL N/A
- Revenue Growth
- AFRI N/A
- RCEL 28.14
- 52 Week Low
- AFRI $7.56
- RCEL $6.90
- 52 Week High
- AFRI $12.00
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- AFRI 33.81
- RCEL 30.28
- Support Level
- AFRI $7.56
- RCEL $9.50
- Resistance Level
- AFRI $8.50
- RCEL $9.85
- Average True Range (ATR)
- AFRI 0.30
- RCEL 0.51
- MACD
- AFRI -0.05
- RCEL -0.18
- Stochastic Oscillator
- AFRI 34.95
- RCEL 20.33
About AFRI Forafric Global PLC
Forafric Global PLC is engaged in production and sale of a variety of wheat flours, Semolina and Pasta and Couscous in Morocco and in more than 45 countries. The two main brands in Morocco are MAYMOUNA and TRIA. The company derives majority of its revenue from Soft wheat.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.